ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 445

What Is the Effect of Statins on the Risk of Rheumatoid Arthritis? Results of a Systematic Review and Meta-Analysis

Elena Myasoedova1, Paras Karmacharya 1, Ali Duarte Garcia 1, John Davis 1, M.Hassan Murad 1 and Cynthia Crowson 2, 1Mayo Clinic, Rochester, MN, 2Mayo Clinic Rochester, Rochester

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: rheumatoid arthritis (RA) and meta-analysis, statin

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: RA – Diagnosis, Manifestations, & Outcomes Poster I: Risk Factors, Predictors, & Prognosis

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The anti-inflammatory and immune-modulating effects of statins suggest that these drugs may influence the risk of developing autoimmune diseases, such as rheumatoid arthritis (RA).  We aimed to perform a systematic review and meta-analysis of studies assessing the risk of RA in statin-users versus non-users.

Methods: We searched Medline from inception to 01/22/2019 and Embase from 1988 to week 03 2019 for all comparative studies that examined the association between statin use and the risk of RA without restrictions on language.  Two reviewers independently selected studies with very good inter-rater agreement (Cohen’s Kappa coefficient 0.90).  Data on study characteristics and adjusted effect estimates were extracted. A random-effects model was used to pool estimates and generate risk ratio (RR) and 95% confidence intervals (CI).

Results: The literature search identified 1,161 references; of which 8 studies (5 cohort and 3 case-control studies) were included in the systematic review.  Six studies comparing statin users vs non-users were included in the meta-analysis and showed no significant difference in the risk of developing RA (RR 1.01; 95%CI 0.88-1.15; I2=65%).  Similar results were shown when cohort studies (RR 1.01; 95%CI 0.93-1.10, I2=17%) or case-control studies (RR 1.01; 95%CI 0.36-2.87, I2=92%) were analyzed separately.  Two studies assessing persistence with or intensity of treatment with statins showed lower risk of RA in persons with higher as opposed to lower treatment persistence or intensity of statin use (pooled RR 0.66; 95%CI 0.5-0.87; I2=83%).

Conclusion: In this systematic review and meta-analysis, observational evidence suggested that statin users had similar risk of RA as non-users.  Considering some imprecision of the effects based on the 95% CIs, potentially with either meaningful benefit or harm of statin exposure on the risk of RA, it appears premature to conclude the lack of effect at this point.  The risk of RA may be lower in patients who have higher as opposed to lower treatment persistence or intensity of statin use, suggesting potential heterogeneity of treatment effect.  More studies at lower risk of bias are needed to further elucidate the impact of statin use on the risk of RA, considering potential differences by dosage, duration of use, study population and other factors.


Disclosure: E. Myasoedova, Pfizer, 2; P. Karmacharya, None; A. Duarte Garcia, None; J. Davis, Abbvie, 5, Pfizer, 2, 5, Sanofi Genzyme, 5; M. Murad, None; C. Crowson, Crescendo Bioscience, 5, Crescendo BioScience Inc., 5, Crescendo Bioscience Inc., 5, Crescendo Biosciences inc., 5, Pfizer, 2.

To cite this abstract in AMA style:

Myasoedova E, Karmacharya P, Duarte Garcia A, Davis J, Murad M, Crowson C. What Is the Effect of Statins on the Risk of Rheumatoid Arthritis? Results of a Systematic Review and Meta-Analysis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/what-is-the-effect-of-statins-on-the-risk-of-rheumatoid-arthritis-results-of-a-systematic-review-and-meta-analysis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/what-is-the-effect-of-statins-on-the-risk-of-rheumatoid-arthritis-results-of-a-systematic-review-and-meta-analysis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology